Beta-ketoacyl reductase inhibitor (TVB-2640), another lipid-lowering drug, is undergoing clinical trials to determine its effectiveness and safety in treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.